Millions of people with serious eye diseases suffer the devastating impact of vision loss on their ability to perform the tasks we take for granted. With no effective treatments available, reading, driving and recognizing faces can become impossible, and independence is lost.
Imagen Biotech, Inc. is a private, venture-backed biopharmaceutical company dedicated to identifying and developing therapeutics for sight-threatening diseases with high unmet medical needs, including dry age-related macular degeneration (dry AMD) which afflicts an estimated 13 million people.
Imagen’s leadership has a proven track record for advancing revolutionary new treatments for blinding diseases. At Eyetech Pharmaceuticals they helped transform the lives of millions of patients with wet age-related macular degeneration (wet AMD) by ushering in the new era of VEGF-targeted drug therapy to preserve vision.
Now at Imagen, and supported by three leading investor groups with significant capabilities and investments in the ophthalmology space, they are directing their specialized ophthalmology industry experience, expertise and network to developing breakthrough therapies for historically untreatable diseases.